Head to Head Review: Cronos Group (NASDAQ:CRON) versus Eton Pharmaceuticals (NASDAQ:ETON)

Cronos Group (NASDAQ:CRON) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Institutional and Insider Ownership

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 7.8% of Cronos Group shares are held by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Cronos Group has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Profitability

This table compares Cronos Group and Eton Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Earnings and Valuation

This table compares Cronos Group and Eton Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59 million	8.12	-$9.45 million	$0.20	16.15
Eton Pharmaceuticals	$79.95 million	19.74	-$4.60 million	$0.38	145.29

Eton Pharmaceuticals has lower revenue, but higher earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Cronos Group and Eton Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0	2	3	0	2.60
Eton Pharmaceuticals	0	2	4	0	2.67

Cronos Group currently has a consensus target price of $2.30, suggesting a potential downside of 28.79%. Eton Pharmaceuticals has a consensus target price of $67.50, suggesting a potential upside of 22.26%. Given Eton Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Cronos Group.

Summary

Eton Pharmaceuticals beats Cronos Group on 11 of the 13 factors compared between the two stocks.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.